TargetGene Biotechnologies

11:30 AM - 11:45 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
TargetGene Biotechnologies has developed and is now seeking to commercialize the most precise and versatile Genome Editing technology.

Recently granted and pending patents in US and elsewhere are based on the (pre-CRISPR) 2011 invention of RNA-directed gene-targeting by the Founders.

TargetGene’s R&D has created highly specific DNA editing solutions for safer therapeutic applications.

The company has strategic partnerships with leading companies for several applications of the technology and is now seeking venture capital.

TargetGene is seeking to fund a preclinical to clinical pipeline for the treatment of Orphan diseases subsequently translatable to hugely lucrative cures of highly prevalent immune disorders.

TargetGene’s platform TGEE technology serves as a programmable molecular “DNA scissors” and incorporates a dual RNA "Guiding System", akin to programming software, which targets it to the precise location in the Genome.

The company is located in Rehovot, Israel
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
TGEE platform
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided